Loading
A phase 3 trial of Trastuzumab brengitecan, Pembrolizumab, Pemetrexed in non-small-cell lung cancer and small-cell lung cancer, run by Sichuan Baili Pharmaceutical Co., Ltd., now recruiting.
A Study of BL-M07D1 vs Pembrolizumab-platinum Chemotherapy in First-line Treatment of HER2-mutant Advanced or Metastatic Non-squamous NSCLC is a phase 3 interventional study registered as NCT07178795 by Sichuan Baili Pharmaceutical Co., Ltd., with 440 participants planned, started 2025-09-29 and due to reach its primary completion in 2027-12. Interventions recorded: BL-M07D1, Pembrolizumab, Pemetrexed, Carboplatin, Cisplatin. Conditions listed: Non-squamous Non-small Cell Lung Cancer. No results are recorded here; the registry entry is the source.
Shares Trastuzumab brengitecan, HER2-mutant non-small-cell lung cancer, SystImmune / Sichuan Biokin, Small-cell lung cancer.
Shares Trastuzumab brengitecan, HER2-mutant non-small-cell lung cancer, SystImmune / Sichuan Biokin, Small-cell lung cancer.
Shares Pemetrexed, Cisplatin, Carboplatin, Small-cell lung cancer.
Shares Pemetrexed, Cisplatin, Carboplatin, Small-cell lung cancer.
Shares Pemetrexed, Cisplatin, Carboplatin, Small-cell lung cancer.
Shares HER2-mutant non-small-cell lung cancer, Pemetrexed, Cisplatin, Carboplatin.
Shares HER2-mutant non-small-cell lung cancer, Pemetrexed, Cisplatin, Carboplatin.
Shares Pemetrexed, Cisplatin, Carboplatin, Small-cell lung cancer.